Funder
The Major Research and Development Project of Innovative Drugs, Ministry of Science and Technology of China
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Wu X, Li Y, Zhang J, Zhang Y, Yu J, Cao G, Chen Y, Guo B, Shi Y, Huang J, Cao Y, Liu X, Wu J, Gordeev MF, Yuan H, Wang W (2018) Short-term safety, tolerability, and pharmacokinetics of MRX-I, an oxazolidinone antibacterial agent, in healthy Chinese subjects. Clin Ther 40(2):322–332.e325.
https://doi.org/10.1016/j.clinthera.2017.12.017
2. Gordeev MF, Yuan ZY (2014) New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem 57(11):4487–4497.
https://doi.org/10.1021/jm401931e
3. Shoen C, DeStefano M, Hafkin B, Cynamon M (2018) In vitro and in vivo activity of contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother.
https://doi.org/10.1128/aac.00493-18
4. Damle B, Labadie RR, Cuozzo C, Alvey C, Choo HW, Riley S, Kirby D (2011) Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongation. Antimicrob Agents Chemother 55(9):4302–4307.
https://doi.org/10.1128/aac.01723-10
5. ICH Guideline E14 (2005) The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献